Boston Scientific Announced FDA Recommended Approval For Expansion Of CRT-Ds

Boston Scientific (NYSE:BSX) announced that the Circulatory System Devices Panel of the FDA has unanimously recommended approval of an expanded indication for its cardiac resynchronization therapy difibrillators (CRT-Ds), which includes the COGNIS CRT-D, according to a Bloomberg report.

Executive Vice President and Group President of Cardiology, Rhythm and Vascular Hank Kucheman said, "Boston Scientific welcomes the panel's decision to recommend expanding the current indication to include the majority of the MADIT-CRT population. If an expanded indication is approved by the FDA, many additional heart failure patients would be eligible for this therapy, which has been clinically proved to slow the progression of this severe and life-limiting condition."